CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting

D.G Courtney, J.E Moore, S.D Atkinson, E.H.A Allen, D.M.L Pedrioli, W.H.I McLean, M.A Nesbit, C.B.T Moore

Research output: Contribution to journalArticle

44 Citations (Scopus)
LanguageEnglish
Pages108-112
Number of pages4
JournalGene Therapy
Volume20
Issue number23
Early online date20 Aug 2015
DOIs
Publication statusE-pub ahead of print - 20 Aug 2015

Keywords

  • CRISPR/Cas9
  • DNA
  • in vitro and in vivo KRT12
  • mutation-specific targeting

Cite this

Courtney, D.G ; Moore, J.E ; Atkinson, S.D ; Allen, E.H.A ; Pedrioli, D.M.L ; McLean, W.H.I ; Nesbit, M.A ; Moore, C.B.T. / CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting. In: Gene Therapy. 2015 ; Vol. 20, No. 23. pp. 108-112.
@article{dbc065a259214b47b0ff5fc93a538bcf,
title = "CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting",
keywords = "CRISPR/Cas9, DNA, in vitro and in vivo KRT12, mutation-specific targeting",
author = "D.G Courtney and J.E Moore and S.D Atkinson and E.H.A Allen and D.M.L Pedrioli and W.H.I McLean and M.A Nesbit and C.B.T Moore",
year = "2015",
month = "8",
day = "20",
doi = "10.1038/gt.2015.82",
language = "English",
volume = "20",
pages = "108--112",
journal = "Gene Therapy",
issn = "0969-7128",
number = "23",

}

CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting. / Courtney, D.G; Moore, J.E; Atkinson, S.D; Allen, E.H.A; Pedrioli, D.M.L; McLean, W.H.I; Nesbit, M.A; Moore, C.B.T.

In: Gene Therapy, Vol. 20, No. 23, 20.08.2015, p. 108-112.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting

AU - Courtney, D.G

AU - Moore, J.E

AU - Atkinson, S.D

AU - Allen, E.H.A

AU - Pedrioli, D.M.L

AU - McLean, W.H.I

AU - Nesbit, M.A

AU - Moore, C.B.T

PY - 2015/8/20

Y1 - 2015/8/20

KW - CRISPR/Cas9

KW - DNA

KW - in vitro and in vivo KRT12

KW - mutation-specific targeting

U2 - 10.1038/gt.2015.82

DO - 10.1038/gt.2015.82

M3 - Article

VL - 20

SP - 108

EP - 112

JO - Gene Therapy

T2 - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 23

ER -